Company Overview
Snapshot
Founded in January 2022 by Shaul Ozeri, NovaPulse operates with 1–10 employees. The company has secured funding across one round from Almeda Ventures and MEDX Xelerator. In September 2022, NovaPulse received investment from Almeda Ventures and MEDX Xelerator, with the Israel Innovation Authority also participating.
Business overview
NovaPulse is a bioconvergence company focused on addressing peripheral artery disease (PAD), specifically targeting claudication patients who experience pain and mobility issues due to insufficient blood supply to their legs. The company develops solutions within the Health Tech & Life Sciences sector, operating in the medical devices and medical treatment & therapeutics categories. NovaPulse's core technology involves implants and it serves the healthcare market, particularly healthcare providers.
Strategic signal
In September 2022, NovaPulse, a bioconvergence startup, secured investment from Almeda Ventures and MEDX Xelerator, with the Israel Innovation Authority also participating. This early-stage funding validates the company's approach to the multi-billion dollar peripheral artery disease market and signals investor confidence in its potential to develop new treatments for claudication patients.
Log in to access full profile ›Company Intelligence Q&A
- When was NovaPulse founded?
- NovaPulse was founded in January 2022.
- Who founded NovaPulse?
- Shaul Ozeri founded NovaPulse.
- What is NovaPulse's primary focus?
- NovaPulse specializes in bioconvergence solutions for the peripheral artery disease market, aiming to treat claudication patients suffering from pain and mobility issues due to insufficient blood supply to their legs.
- Which investors participated in NovaPulse's funding round?
- In September 2022, NovaPulse received investment from Almeda Ventures and MEDX Xelerator, with the Israel Innovation Authority also participating.
- What is NovaPulse's product stage?
- NovaPulse's product is currently in the Clinical Trial stage, focusing on developing solutions for peripheral artery disease.